Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

Strosberg, Jonathan R.; Fisher, George A.; Benson, Al B.; Anthony, Lowell; Arslan, Bülent; Gibbs, John F.; Greeno, Edward; Iyer, Renuka; Kim, Michelle K.; Maples, William J.; Philip, Philip A.; Wolin, Edward M.; Cherepanov, Dasha; Broder, Michael S.

doi:10.3748/wjg.v21.i8.2450

Cited by 12 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nuclear-associated antigen Ki-67 is an important cell proliferation-associated nuclear antigen (Strosberg et al, 2015b). It is believed that the occurrence of cancer is closely related to cellular hyperproliferation.…”

Section: Introductionmentioning

confidence: 99%

Effect of everolimus on the expression of Ki-67 and caspase-3 in patients with neuroendocrine tumors

Zhang

Cheng

et al. 2017

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Tumors, especially neuroendocrine tumors (NETs), can cause adverse effects on human health. The expression and significance of Ki-67 and caspase-3 in NET remain to be further explored. Everolimus is an important drug used for the treatment of NETs. In this study, we aimed to investigate whether everolimus exerts anti-tumor effects by suppressing the expression of Ki-67 and caspase-3 in NET. Tumor (different developmental stages) and adjacent tissues were collected from patients with NET. The expression of Ki-67 and caspase-3 were detected in 244 paraffin sections of NET using immunohistochemistry. RT-PCR and western blot were used to detect the expression of Ki-67 and caspase-3 at mRNA and protein levels, respectively. The patients (N = 244) were randomly divided into everolimus-intervention and control groups. RT-PCR and western blot were used to measure the expression changes of Ki-67 and caspase-3 before and after everolimus treatment. The rates of Ki-67 expression in NET grades 1-6 were 14.2, 22.1, 37.5, 59.9, 69.9, and 77.8%, respectively. The difference between the groups was significant. The rates of caspase-3 expression in NET grades 1-6 were 28.6, 33.3, 31.3, 60.0, 80.0, and 88.9%, respectively, and the difference between groups was significant. Moreover, the expression of Ki-67 and caspase-3 showed a significant negative correlation. The expression of Ki-67 decreased while that of caspase-3 increased after everolimus treatment. In conclusion, the decrease in Ki-67 expression and increase in caspase-3 expression after everolimus treatment indicated that everolimus exerted its anti-cancer effect by regulating the expression of Ki-67 and caspase-3.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of everolimus on the expression of Ki-67 and caspase-3 in patients with neuroendocrine tumors

Zhang

Cheng

et al. 2017

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Similarly, according to a recently published consensus article on the appropriateness of a variety of systemic treatments in patients with pNETs, everolimus, sunitinib, and cytotoxic chemotherapy were all defined as appropriated as the first line therapy in patients with hormonally functioning or progressive tumours, without significant differences in ratings (Strosberg et al 2015).…”

Section: Discussionmentioning

confidence: 99%

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

Gallo

Malandrino

Fanciulli

et al. 2017

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Results We identified eight retrospective published studies, two prospective published studies, and five registered clinical trials. Moreover, we analyzed the content of four widespread international guidelines. Conclusions Our critical review confirms the lack of highquality data to recommend everolimus as the first line therapy for pNETs. The ongoing clinical trials reported in this review will hopefully help clinicians, in the near future, to better evaluate the role of everolimus as the first line therapy for pNETs. However, at the moment, there is already enough evidence to recommend everolimus as the first line therapy for patients with symptomatic malignant unresectable insulin-secreting pNETs, to control the endocrine syndrome regardless of tumour growth.

show abstract

“…The expert agreement, average scores, and coefficient of variation (CV) are internationally taken as common parameters for determining consensus in the Delphi process. However, there are controversies regarding the parameter thresholds (Hasson, Keeney & McKenna, 2010; Flores, Marshall & Cordina, 2014; Slade et al, 2014; Strosberg et al, 2015; Jang et al, 2015). We integrated the parameters with a modified criterion to avoid important items from potentially being removed.…”

Section: Methodsmentioning

confidence: 99%

An assessment for health education and health promotion in chronic disease demonstration districts: a comparative study from Hunan Province, China

Jin

Yin

et al. 2019

PeerJ

View full text Add to dashboard Cite

Background Cost-effective strategies of chronic disease control, integrated health education and health promotion play important roles in the programs of chronic disease demonstration districts in China. The performance of these districts can be directly assessed by their health education and promotion work. However, there have been only a few performance assessments done on these programs, most of which made without the inclusion of proper quality indicators. This study was designed to establish a framework of indicators for outcome evaluation of health education and promotion efforts in Chinese districts, and explore the factors involved in promoting these efforts. Methods A modified two-round Delphi survey was first used to construct quality indicators on a nine-point Likert scale. With those indicators, the rank sum ratio (RSR) method was then conducted through rank conversion and parametric statistics, to assess and classify the performance of ten districts or counties randomly chosen both from demonstration and non-demonstration districts in the Hunan province. Results The Delphi process produced seven themes and 25 sub-themes as quality indicators. The seven themes included organizational management, financial support, professional personnel, health education and promotion, residents’ health awareness and behaviors, residents’ satisfaction, and residents’ health literacy. The districts were classified into four levels by RSR as follows: One demonstration district at the first-ranked level, five other demonstration districts at the second-ranked level, all non-demonstration districts at the third-ranked level. None were at the fourth-qualified level. Discussion Chronic disease demonstration districts performed better on the work of health education and health promotion than the non-demonstration districts. The work should be focused on the following measures of chronic diseases: organizational management, financial support, media-related broadcasting, technical support, community-based promotion and supportive environment, and people’s enhanced awareness and health literacy.

show abstract

Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

Abstract: Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs.

Cited by 12 publications

References 33 publications

Effect of everolimus on the expression of Ki-67 and caspase-3 in patients with neuroendocrine tumors

Effect of everolimus on the expression of Ki-67 and caspase-3 in patients with neuroendocrine tumors

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

An assessment for health education and health promotion in chronic disease demonstration districts: a comparative study from Hunan Province, China

Contact Info

Product

Resources

About